AstraZeneca Vaccine Less Effective Against South Africa Variant

AstraZeneca Plc’s Covid-19 vaccine has shown limited efficacy against mild disease caused by the variant first identified in South Africa, according to early data in a small phase trial.

Efficacy against severe Covid-19 cases, hospitalization and deaths was not yet determined, “given that subjects were predominantly young healthy adults,” a spokesperson for AstraZeneca said in a statement.

None of the participants in the study died or was hospitalized, according to the Financial Times, which first reported on findings of the study.

The study, with a relatively small sample size of more than 2,000 individuals, hasn’t yet been peer-reviewed and is due to be published on Monday, the newspaper said. Patients in the randomized, double-blind study had a median age of 31.

“We do believe our vaccine could protect against severe disease, as neutralising antibody activity is equivalent to that of other Covid-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to 8-12 weeks,” the AstraZeneca spokesperson said.

Initial data indicates other immune responses, such as T-cell responses, may remain intact in the South African variant, the spokesperson added.

The variant first identified in South Africa is emerging as a key threat to the world’s prospects for ending the pandemic as countries roll out initial vaccine doses. Although vaccine makers said their shots appear to maintain effectiveness against the UK varia

About the author


Leave a Comment